- 1 Heterogeneity of the placenta in health and disease explored through integrated
- 2 histology, gene expression and modelling
- Hannah Ee Juen Yong^{1,2*}, Kasia Maksym^{3,4*}, Muhammad Ashraf Bin Yusoff³, Esteban 3
- Salazar-Petres¹, Tatiana Nazarenko^{3,5}, Alexey Zaikin^{3,5}, Anna L David^{3,4,6}, Sara L 4
- 5 Hillman^{3,4}+, Amanda N. Sferruzzi-Perri¹+
- 6
- 7 *contributed equally; joint first author
- 8 +contributed equally; joint last and corresponding author
- 9
- 10 ¹Centre for Trophoblast Research,
- Department of Physiology, Development and Neuroscience 11
- University of Cambridge 12
- Cambridge UK 13
- CB2 3EG 14
- 15
- 16 ²Singapore Institute for Clinical Sciences,
- 17 Agency for Science, Technology and Research,
- Singapore 18
- 19
- ³ Elizabeth Gareth Anderson Institute for Women's Health, 20
- 21 University College London,
- 22 84-86 Chenies Mews, London UK
- 23 WC1E 6HU
- 24 ⁴ Fetal Medicine Unit
- 25 Elizabeth Gareth Anderson Wing,
- 26 University College Hospitals NHS Trust,
- 27 25 Grafton Way, London UK
- WC1E 6DB 28
- 29
- ⁵ Department of Mathematics, 30
- 31 University College London,
- 32 London UK NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 WC1E 6AE

- 34
- ⁶ National Institute for Health Research University College London Hospitals Biomedical
- 36 Research Centre, 149 Tottenham Court Road, London W1T 7DN
- 37
- 38 Correspondence:
- 39 Amanda Sferruzzi-Perri (<u>ans48@cam.ac.uk</u>)
- 40 Sara Hillman (<u>sara.hillman@ucl.ac.uk</u>)
- 41

42 **Abstract:**

Fetal growth restriction (FGR) is a leading cause of perinatal morbidity and mortality. Altered 43 44 placental formation and functional capacity are major contributors to FGR pathogenesis. 45 Relating placental structure to function across the placenta in healthy and FGR pregnancies 46 remains largely unexplored but could improve understanding of placental diseases. We investigated integration of these parameters spatially in the term human placenta using 47 48 predictive modelling. Systematic sampling was able to overcome heterogeneity in placental 49 morphological and molecular features. Defects in villous development, elevated fibrosis, and 50 reduced expression of growth and functional marker genes (IGF2, VEGA, SLC38A1, SLC2A3) were seen in age-matched term FGR versus healthy control placentas. Characteristic 51 histopathological changes with specific accompanying molecular signatures could be 52 53 integrated through computational modelling to predict if the placenta came from a healthy or FGR pregnancy. Our findings yield new insights into the spatial relationship between placental 54 structure and function and the aetiology of FGR. 55 56 Key words: Placenta, FGR, modelling, morphology, growth genes, transport 57

58

60 **Introduction:**

The human placenta is a highly specialized organ in pregnancy, whereby normal functioning 61 62 is critical to fetal development and long-term health. By acting as a functional interface 63 between the maternal and fetal circulation, it is responsible for maternal-fetal substrate 64 exchange, protects the fetus from immune rejection by the mother and secretes hormones, which maintain pregnancy and promote healthy fetal growth and development^{1,2}. This complex 65 66 organ is structurally heterogeneous, not only in terms of its broad spatial macroscopic 67 characteristics with multiple cotyledons and vascular supply, but also at the microscopic level 68 of the villous tree and trophoblast. Even in pregnancies that deliver at term without any apparent pathology, novel techniques such as micro-CT are now describing the large degree of 69 heterogeneity of vascular density and branching in the placenta³. In addition, computational 70 71 models have predicted that local heterogeneity in placental vascular structure can have major impacts on the resistance of the feto-placental circulation and placental dysfunction⁴. 72 73 Investigating the spatial relationships between changes in gene expression and structural 74 differences in the placenta is important, so that we may better elucidate the potential functional 75 effect of placental pathology in obstetric disease.

76

77 Fetal growth restriction (FGR) is a major cause of perinatal morbidity and mortality. The risk of *in utero* or neonatal death is especially high amongst growth restricted fetuses and neonates 78 who are commonly born preterm⁵. In some regions of the world, FGR and prematurity account 79 for 80% of neonatal deaths⁶. FGR is diagnosed when a fetus fails to reach their genetically 80 81 predefined growth potential and is often identified by feto-placental ultrasound features (such as increased umbilical artery resistance to blood flow), and subsequently confirmed through 82 83 placental histopathology⁷. The gestational age at diagnosis is used to further subdivide FGR into early-onset, detected before 32 weeks of gestation, and late-onset according to 84 international consensus⁸. Neonates born following FGR have an increased risk of developing 85 86 health problems, both in the immediate postnatal period including low blood sugars and poor temperature regulation and feeding, but also in later adult life in the form of cardiovascular and 87 metabolic disease^{9,10}. Management of pregnancies affected by FGR can be challenging, as 88 timing of delivery has to be judged well, to balance the hazards of preterm birth against the 89 90 risks of irreversible damage secondary to intrauterine hypoxia and nutritional deficiency or even stillbirth¹¹. 91

93 The placenta of FGR pregnancies is characterized by reduced syncytiotrophoblast surface area, increased thickness of the exchange barrier formed by the trophoblast and fetal capillary 94 endothelium and an increase in placental apoptosis¹²⁻¹⁵. Whilst it is recognized that there are 95 96 key mediators of fetal growth that are influenced by placental function including but not limited to transfer of gases¹⁶, glucose^{17,18}, lipids¹⁹ and amino acids^{18,20}, understanding the mechanisms 97 through which placental histological changes might be affecting these pathways remains a 98 99 challenge. Nuanced, integrated investigations will better delineate the underlying functional mechanisms related to the histological changes observed in the placenta. Experimental animal 100 101 data has highlighted central roles that certain structural and functional changes play in the placenta to fetal growth outcomes²¹⁻²⁵. However, data on how structure *and* molecular changes 102 together impact on function and on each other, even in the form of nutrient transporter 103 expression, are scarce or not available for the human placenta^{26,27}. 104

105

Better understanding of how placental structure relates to functional capacity is further 106 107 optimized through robust placental sampling protocols. Methodological errors arise from differences in sampling and/or tissue processing, which has previously hampered the 108 reproducibility and possible extrapolation of placental studies^{28,29}. Systematic uniform random 109 110 sampling involves random selection of the first sampling site, with subsequent sites dictated by a pre-made sampling interval. This method is recommended to ensure representative and 111 unbiased sampling of the placenta 29,30 . It is a simple method, allowing for even coverage of the 112 placenta and ensures that all sites can only be selected once²⁹. In practice, however, systematic 113 114 uniform random sampling has limitations. Firstly, its lack of bias may be compromised if the pre-determined sampling interval coincides with a natural pattern existent in the placenta³⁰. 115 116 Secondly, placentae templates designed for systematic uniform random sampling assume all 117 placentas to be roughly circular in shape, with central umbilical cord insertion. This assumption 118 of a uniform shape and cord insertion however is incorrect. Although studies do show that mean placental chorionic shape at term is round, deviations in placental shape are associated 119 with reduced placental efficiency³¹. In addition, the site of umbilical cord insertion appears to 120 121 be related to placental function, with a marginal cord insertion near the outer boundary of the placenta being associated with a more asymmetric chorionic vessel structure³², which has been 122 associated with FGR, stillbirth and neonatal death³³. 123

124

125 While analysis of single sites may miss important histopathological and functional changes, multiple site collection poses analytical challenges, and methods may still fail to identify 126

127 critical differences within placentas affected by pathology, such as FGR. Statistical modelling allows for the exploration and integration of multiple data points from the same sample to 128 129 provide more accurate interpretation of functional consequences. Moreover, the use of 130 modelling to predict regional and disease state differences has high translational potential, for 131 example providing an explanation for why the pregnancy was compromised and which baby may benefit the most from early health monitoring and/or postnatal intervention. With this 132 133 study we therefore, firstly sought to better understand if systematic uniform random sampling methods could be optimised to the challenges that FGR placentas pose. Secondly, we sought 134 135 to characterise the degree of detailed histological and molecular heterogeneity between multiple samples in healthy and FGR placentas and to examine potential links between 136 137 histological changes and the expression of genes involved in placental formation, transport, and transcriptional regulation, and their relationships with fetal growth/pregnancy outcome. 138 139 Finally, in a proof of principle approach, we integrated these changes into a novel analysis model to better delineate the significance of the placenta in health and disease. 140

141

Results: 142

143 **Patient characteristics**

144 We matched FGR cases and controls for maternal age, booking BMI, mode of delivery and infant sex (Table 1) with expanded clinical data available (Supplementary Table 1). 145 146 Nonetheless, several significant differences in clinical characteristics were still observed. FGR cases were more likely to be non-White and delivered infants with lower birth and placental 147 weights about a week earlier, although all delivered at term ($>36^{+6}$ weeks of gestation). 148

149

Characteristics	Control (N=9)	FGR (N=7)	P-value
Maternal age	34.44 ± 1.84	32.00 ± 1.16	0.339
Maternal ethnicity	8 white, 1 non-white	2 white, 5 non-white	0.035
Booking BMI (kg/m ²)	24.67 ± 1.51	24.47 ± 2.75	0.946
Mode of delivery	4 vaginal deliveries, 5 caesarean sections	2 vaginal deliveries,5 caesarean sections,	0.620
Gestational age at delivery (weeks)	39.14 (39.07 – 39.79)	38.29 (37.29 – 39.00)	0.006
Infant sex	4F, 5M	2F, 5M	0.633
Infant birthweight (kg)	3.53 ± 0.13	2.33 ± 0.18	< 0.001

150 **Table 1: Patient characteristics.**

	Placental weight (g)	478.9 ± 16.6	340.7 ± 31.0	0.001			
151	Data are presented as mean \pm SEM and were analysed by Student's t test or Mann-Whitney U						
152	test. Categorical data were analysed by 2 X 2 contingency table with Fisher's Exact Test. BMI,						
153	body mass index; F, femal	e; M, male.					
154							
155	Stereological analysis of	placental morphology					
156	Comparing stereological f	indings by sampling site	e within the FGR or cont	rol groups showed			
157	no significant differences between samples taken from the central and peripheral regions of the						
158	placenta (Supplementary Table 2). Hence, we averaged the data of the central and peripheral						
159	regions of each placenta to	compare by pathology	(Table 2). Taking into co	onsideration a false			
160	discovery rate of 5% for	multiple testing, FGR	placentas had significant	ntly lower volume			
161	densities of intermediate	villi, syncytial knots	and higher volume den	sities fibrosis and			
162	capillaries. Once placental	weight was accounted	for, FGR cases showed of	decreased volumes			
163	of intervillous spaces, inter	rmediate villi, terminal v	villi, syncytial knots, troph	oblast and stromal			
164	components, and increased	d volume of fibrosis con	mpared to control placent	tas. There were no			
165	differences in any measur	e of barrier thickness, s	urface area, surface dens	ities and diffusion			
166	capacities between FGR an	nd control placentas; exc	cept that FGR placentas ha	ad a decreased villi			
167	surface area.						

Table 2: Morphological differences in the placenta by pathology 169

	Control (N=9)	FGR (N=7)	P-value
			(^FDR)
Volume density (cm ³ /g)			
Intervillous space	0.37±0.01	0.36±0.02	0.447
Stem villi	0.06±0.01	0.06±0.01	0.895
Intermediate villi	0.12±0.01	0.08±0.01	0.008*
Terminal villi	0.42±0.02	0.4±0.03	0.474
Syncytial knots	0.02±0.00	0.01±0.00	0.002*
Fibrosis	0.01±0.01	0.1±0.02	0.001*
Trophoblast	0.32±0.01	0.34±0.03	0.583
Stromal	0.55±0.02	0.45±0.05	0.058
Capillary	0.13±0.01	0.21±0.03	0.016*
Volume (cm ³)			
Intervillous space	179.73±9.45	119.44±10.77	0.001*
Stem villi	27.83±3.2	20.17±4.25	0.163
Intermediate villi	55.4±4.41	25.48±2.43	<0.001*
Terminal villi	200.73±10.54	135.3±16.23	0.003*
Syncytial knots	8.39±0.78	2.44±0.71	<0.001*
Fibrosis	5.88±3.24	37.02±7.43	0.001*
Trophoblast	153.5±6.83	114.7±13.69	0.017*
Stromal	263.09±15.46	153.23±21.66	0.001*
Capillary	62.3±5.04	72.78±13.76	0.445
Barrier thickness (µm)			
Arithmetic mean	2.83±0.08	2.85±0.18	0.912
Harmonic mean	2.14±0.07	2.24±0.14	0.500
Thickness uniformity index (a	1.32±0.01	1.48±0.08	0.044
measure of thickness variability)			
Surface density (cm ² /cm ³)			
Villi	610.45±23.85	630.28±44.68	0.683
Fetal capillary	298.26±19.81	401.92±48.29	0.048
Surface area (m ²)			

medRxiv preprint doi: https://doi.org/10.1101/2022.05.31.22275522; this version posted February 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4	4.0 International license .
--------------------------------------	-----------------------------

Villi	11.68±2.88	10.59±1.55	0.009*
Fetal capillary	6.27±1.7	6.89±1.23	0.576
Theoretical diffusion capacity	95.29±4.86	70.26±11.5	0.047
(cm²/min/kPa)			
Specific diffusion capacity	27.2±1.49	29.47±3.99	0.567
(cm²/min/kPa/g)			

170 Data presented as mean \pm SEM and analysed by t test with FDR (false discovery correction)

171 correction at 5%. * denotes significant findings that passed the 5% FDR.

172

173 Placental expression of growth factors and nutrient transporters

174 We also evaluated relative mRNA expression of selected growth factors and nutrient transporters (Figure 1) that have been previously implicated in transcriptional control or with 175 compromised fetal growth in humans and animal models of FGR³⁴⁻³⁹. Placental *IGF2*, *SLC2A3* 176 177 and SLC38A1 expression was significantly lower for FGR versus controls, regardless of 178 sampling location (Figures 1A, 2D and 2E). VEGFA expression was significantly lower in the peripheral region as compared to the central region of FGR placentas, while no statistical 179 180 difference was identified in the central region between cases and controls (Figure 1B). Only 181 SLC2A1 expression was significantly increased in FGR placenta as compared to controls, 182 independent of sampling location (Figure 1C). No differences in mRNA expression of and 183 SLC38A2 were observed between FGR and control placentas or by sampling location (Figure 1F). In controls, placental *HNF1A* expression was higher in the peripheral region as compared 184 to the central region (Figure 1G), but no differences were identified for FGR. 185 186



188 Figure 1: Relative mRNA expression of selected growth factors and nutrient transporters

in control and FGR placentas. Expression of growth factors (IGF2, VEGFA), and 189 190 transporters (SLC2A1, SLC2A3, SLC38A1, SLC38A2 and the transcription factor HNF1A), 191 were evaluated by qPCR. A total of 3 outliers were excluded; 1 control peripheral value for 192 VEGFA, and 1 control central value and 1 control peripheral value for HNFIA. Data are presented with individual data points with mean ± SEM and analysed with two-way ANOVA, 193 194 followed by Sidak's post hoc test for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, 195 ****p<0.0001.

196

Associations between placental morphology and expression of functional genes 197

198 We next evaluated relationships between placental morphology and the expression of growth 199 factor and nutrient transporter genes within the different sampling sites, and between control and FGR groups using Pearson's r coefficient (Figure 2). In FGR placentas, several inverse 200 201 correlations were identified between expression of IGF2, VEGFA, SLC38A1 and SLC2A3 and the volume of terminal villi, trophoblast, and capillary volume predominantly in the peripheral 202 203 region of FGR placentas. Inverse correlations with fibrosis volume were also observed for 204 expression IGF2, VEGFA, SLC38A1 and SLC2A3 in the central region of FGR placentas. 205 Additionally, the relative expression of IGF2, VEGFA, SLC38A1 and SLC2A3 genes was 206 inversely correlated with barrier thickness uniformity index and both maternal blood spaces 207 and fetal capillaries surface densities in the FGR placenta (central and peripheral sites), although no significant correlations were detected for the control placenta. Moreover, the 208 209 expression of IGF2, SLC38A1 and SLC2A3 genes negatively correlated with both theoretical and specific diffusion capacity in FGR, but not control placentas. In contrast, FGR expression 210 211 of HNF1A showed a positive correlation with specific diffusion capacity in the peripheral 212 region. Positive correlations between the expression of all genes measured and fibrosis and 213 stromal volumes were found for the peripheral region of control placentas, but not FGR placentas. Positive relationships were also seen for expression of VEGFA and HNF1A with the 214 stem villi volume in central sites of control placentas. 215



217

218 Figure 2. Correlations between stereological parameters and the relative expression of functional genes in the placenta. Pearson's r coefficient was plotted and used to indicate 219 strength of relationship between data (0: low, 1: high) and direction of correlation (+ sign: 220 221 direct correlation and – sign: inverse correlation). Analysis was performed on each sampling site and experimental group (control and FGR) separately. Sample size was 36 for control and 222 223 24 for FGR. *: p < 0.05, correlation is statistically significant.

224

225 **Predictive modelling**

226 To evaluate the information gained from different placental regions/sampling sites (only peripheral, only central, or both together) and data types (only stereological data, only qPCR 227 data or both together), we considered all their possible combinations using predictive 228 modelling (construction of classifiers that would make it possible to distinguish patients in the 229 control group from patients with FGR). As predictive modelling was carried out using three 230 231 machine learning (ML) methods; xgbTree, glmnet and nnet, this resulted in 27 models for consideration. The binary outcome of FGR was used as an outcome with chosen set of features 232 (only stereological data, only qPCR data, both data types together) used as predictors. The 233 predictive performance of each model was assessed using a leave-one-out cross-validation 234 (LOOCV) scheme: the prediction was made for each patient (with all measurements) by 235 236 excluding (withholding) it from the dataset, training the classifier on the remaining (independent) samples, and then generating predictions for the withheld samples using the 237 238 trained model. Using predictions on the training subset (on each round of LOOCV procedures), 239 the best threshold (corresponding to the best sum of sensitivity plus specificity) distinguishing

240 controls from FGR cases was found and a binary result was calculated for each withheld sample 241 (1 indicated FGR if the prediction was above the threshold, and 0 indicated control if it was 242 below the threshold). Through all rounds, LOOCV procedure binary results were collected for 243 withheld samples and performance was assessed using by these sets of predictions. 244 Performance was estimated using areas under the ROC curve (AUCs) in 2 ways: "AUC for all samples" and "AUC for all patients", as described in Methods. For each combination of 245 246 "placenta part + type of measurement + ML model" two such AUC values were obtained. Full 247 results of these analyses can be found in Table 3 (in addition, we provide a complete table of 248 errors for each patient in Supplementary Table 3). For a simplified visualization of these 249 results, we considered the distributions of results (AUCs) of different types of ML models on 250 different types of data obtained in different parts of the placenta for all patients and for all their 251 samples separately (Figure 3). This plot clearly shows that among the considered models, the 252 best are those based on measurements performed on the peripheral parts of the placenta and using stereological and qPCR data together. As shown in Table 3, the best model was found to 253 be *nnet*, i.e., the model using simple artificial neural networks for a classification. This model 254 255 gave the best result for both "AUC for all samples" (0.979) and "AUC for all patients" (0.917). 256 By considering the stereological and qPCR data separately, the stereological data showed a 257 greater predictive power than the qPCR data (Figure 3, for all variants), which, may be due to 258 the clearly different interdependences of the stereological parameters of the control group and 259 the FGR group (the most significant interdependences are presented in Supplementary Figure 1). However, a combination of stereology and qPCR data works better than just stereology for 260 261 analyses on peripheral parts of the placenta (Figure 3). The results obtained on the central parts 262 of the placenta were lower than the results obtained on both parts of the placenta or only on the 263 peripheral (boxplots for the central parts are slightly lower than the other options). Moreover, 264 results using only peripheral parts were better than using a combination of both parts. Thus, 265 the best model would be that based on measures made on the peripheral parts of the placenta using stereological and qPCR data together. 266

- 267
- 268

269 Table 3: Predictive modelling results using different machine learning methods.

Peripheral & Central									
	Stereology			qPCR		Stereology & qPCR			
	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
AUC for all samples	0.899	0.913	0.927	0.705	0.733	0.719	0.875	0.92	0.948
AUC for all patients	0.611	0.861	0.917	0.639	0.528	0.528	0.694	0.861	0.917
	1	1	Р	eripheral	1	<u>.</u>		1	1
	St	tereology			qPCR		Stereo	logy & qI	PCR
	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
AUC for all samples	0.903	0.938	0.924	0.681	0.694	0.681	0.819	0.938	0.979
AUC for all patients	0.861	0.917	0.861	0.556	0.556	0.556	0.778	0.917	0.917
				Central					
	St	tereology			qPCR		Stereo	logy & qF	PCR
	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
AUC for all samples	0.889	0.903	0.903	0.722	0.694	0.722	0.826	0.889	0.889
AUC for all patients	0.778	0.861	0.861	0.611	0.611	0.611	0.722	0.861	0.806

270 **Results for each combination of "placenta part + type of measurement + ML model"** The 271 best version of the model is *nnet* model (highlighted in bold) on peripheral parts of placenta using stereological and qPCR data together. In this case, "AUC for all patients" = 0.917272 273 (corresponding to an error for just one patient-case in a sample of 15 patients: 9 controls and 6 FGR), and "AUC for all samples" = 0.979 (corresponding to an error for only one 274

- 275 measurement, a FGR in a set of 15*4 samples: 9*4 control samples and 6*4 FGR samples). A
- 276 complete table of errors is given in Supplementary Table 3.
- 277



278

Figure 3: Distributions of AUCs, i.e., the performance results of different types of models 279 280 on different types of data obtained on different parts of the placenta for all patients and 281 for all their measurements separately.

282

Discussion 283

284 There was no significant variability in the morphological features of the placenta within and between the peripheral and central sites of the placenta, regardless of whether they came from 285 286 a healthy or FGR pregnancy. In addition, the findings indicate that alterations in placental 287 morphology may be uniform across the placenta in late-onset FGR pregnancies without other complications, such as pre-eclampsia, that can lead to more variable histological changes 288 289 across the placenta⁴⁰.

290

Despite established evidence that the placenta drives a number of the 'great obstetrical' 291 292 syndromes, which includes FGR, the relatively poor understanding of underlying placental mechanisms makes interpretation of how they contribute to clinical presentations difficult⁴¹. 293 294 Heterogeneity within the placenta is thought to be responsible for some of the difficulties in directly relating disease state to placental findings. Our results suggest that the systematic 295 296 sampling technique that we used was able to overcome potential morphological spatial 297 heterogeneity of the term placenta, whether from normal or late FGR pregnancies. Indeed,

peripheral versus central region comparisons revealed unique features in gene expression correlations and predictive modelling results. These findings enable more clinical interpretations to be made of the results and indicate that using of this sampling technique may improve reproducibility between placental studies. This analysis suggests that at least a peripheral and central sample should be taken when assessing placental function, particularly in disease states.

304

Morphological differences between the control and FGR placenta are consistent with findings 305 of others⁴², and indicate villous mal-development, with fewer mature intermediate and terminal 306 villi and reduced villous surface area, as well as elevated fibrosis. The increased villous 307 308 capillary density and reduced syncytial knots in the studied FGR placentas are novel findings 309 and may reflect adaptive responses to hypoxic-reoxygenation events secondary to reduced utero-placental and/or feto-placental flows in FGR pregnancies⁴³⁻⁴⁵. Moreover, these beneficial 310 changes in placental morphology may be the explanation for the FGR babies in our study 311 312 reaching near full term. Hence, morphological findings provide a clue to underlying placental mechanisms that may be subject to change, with the resultant amelioration of disease and 313 314 improvement to fetal outcome, if they can be enacted in utero. There is already significant interest in delivery of targeted agents to the uterine arteries to improve blood flow⁴⁶. Delivery 315 of agents to target specific areas of pathology and functional deficit within the placenta to 316 317 improve the clinical condition may also be a potential therapeutic option.

318

319 Our approach to combine morphological assessments with gene expression aimed to identify 320 some key aetiological pathways for the pathology seen. Expression of placental IGF2, SLC2A3 321 and *SLC38A1* was lower across the FGR placenta, correlating with volumes and other specific 322 placental features, suggesting a global role for these molecules in placental structure and 323 development in the presence of FGR. Indeed, *IGF2* is known to be important for the formation of the placental exchange interface in humans, among other species^{38,39,47}, and is expressed at 324 lower levels in placentas showing FGR/small for gestational age in some^{48,49}, but not all 325 studies⁵⁰. Prior work has shown that a genetic deficiency of *SLC2A3* in mice leads to FGR ³⁷ 326 which supports our findings, but is in contrast to other work reporting an upregulation of its 327 encoded protein in the human placenta of late-onset FGR⁵¹. Of the system A amino acid 328 transporters expressed by the human placenta, SLC38A1 is key for system A activity at term⁵². 329 330 Other work has also shown that placental system A activity is reduced in explants prepared from term FGR placentas⁵³. VEGFA was significantly lower in the peripheral region of the 331

332 placenta in FGR and correlated to the following placental pathology (terminal villi, trophoblast and capillary volume) that might suggest a causal association. This is consistent with other 333 work reporting lower placental VEGFA expression at term in late onset FGR^{54,55}, and the 334 involvement of angiogenic factors more generally in normal and pathological pregnancies⁵⁶. 335 336 Our findings also have relevance for emerging pre-clinical research in placenta-directed gene 337 therapy for FGR, including the utility of insulin-like growth factors and angiogenic 338 regulators⁵⁷. *HNF1A* was more highly expressed by the peripheral region compared with 339 central region in healthy, but not FGR placentas. Little is known about the function of HNF1A in the placenta, although the human tissue atlas⁵⁸ indicates it is abundantly expressed by the 340 villous syncytiotrophoblast ⁵⁹. Recent work has highlighted that *HNF1A* may regulate a large 341 number of genes in trophoblast cells⁶⁰ and mediate metabolic changes⁶¹, which could be 342 important for the placental support of fetal growth, more broadly. 343

344

Using a modelling approach in our discovery cohort, we demonstrated the potential of 345 346 predicting outcome (control or FGR) based on stereology and qPCR data. Stereology and qPCR 347 measurements taken from the peripheral part of the placenta, and analysed together, have the 348 highest predictive power. To avoid any possible overfitting of the models, we did not perform 349 any feature selection in advance for tuning of the algorithm hyperparameters. Despite this, we 350 were able to obtain predictions with very high accuracy, as, in fact, for the best model, only 351 one sample out of 60 (4 samples from peripheral placenta part for each of 15 patients) considered was predicted incorrectly. Indeed, this subject was one that was most likely to be 352 353 misclassified in all of the tested models. Nevertheless, we found that the morphological data 354 clearly shows separation of features for control and FGR placentas and probably, this made it 355 possible to obtain high quality constructed models. For the present study, we used a very strict 356 LOOCV. Whilst modelling predictions were poor when qPCR data were used alone, adding 357 these data to the analysis of stereology data improved prediction, hence, confirming importance of qPCR data and underlying link of these data with functional features. Whilst our modelling 358 approach shows potential, future work would benefit from utilising a larger dataset, with 359 360 extremes of pathology, to validate the model.

361

362 Overall, our data add to current understanding of placental function through comprehensive 363 sampling of healthy placentas and those affected by disease (FGR) with careful deep 364 histological analysis, integrated with expression of genes involved in key biological pathways regulating placental function. Whilst, our modelling approach requires validation, with further 365

pathology analysed, it offers the promise of better diagnostic yield and novel insight intobiological pathways that affect FGR pregnancies.

368

369 Material and methods:

370 Placental tissue collection and sampling

Subjects were recruited from University College London Hospital NHS Foundation Trust, 371 372 London, UK with ethics approval from the South-Central Oxford A research ethics committee (17/SC/0432). After written informed consent was obtained, term placental biopsies were 373 collected from subjects diagnosed with late-onset FGR (n=7, FGR detected after 32 weeks' 374 gestation and an estimated fetal weight and/or abdominal circumference below 3rd centile on 375 population-based charts used clinically⁶²), and from control subjects with appropriately grown 376 fetuses (n=9 birthweight $>10^{th}$ centile and $<90^{th}$ centile). Data on maternal pre-existing 377 conditions, previous obstetric history, ultrasound examination, and pregnancy complications 378 379 were collected at the time of recruitment.

380

381 Placentas were weighed and sampled within 30 minutes of delivery. Sampling sites were 382 chosen to be representative of four central and four peripheral regions always relative to cord 383 insertion (Figure 4A). In marginal cord insertions, the placenta was orientated with the cord 384 anterior. Sampling then took place relative to the cord insertion as in other cases. This meant 385 there was one site that had less tissue to sample from initially, in non-central cord insertions, but that ultimately the same amount of tissue was sampled, and that tissue selection was directly 386 387 related to the cord in the same way as all other samples. For each placenta, 8 tissue biopsies 388 (with maternal tissue and fetal chorionic plate removed) were snap frozen using liquid nitrogen or dry ice and stored at -80°C. Neighboring sampling sites were then immersion-fixed in 4% 389 390 paraformaldehyde.



393 394

395 Figure 4. Diagram showing sampling of placenta (A) and main parameters measured in histological sections of placenta (B-D). (A) Dotted lines indicate where the placenta should 396 397 be cut with a sterile histology knife. Red boxes with single letters indicate inner sections. Yellow boxes with double letters indicate outer sections. Green rectangles represent samples 398 399 taken for RNA sampling. The central blue circle represents the umbilical cord (cut). (**B-D**) Representative histological sections of term human placenta. Stereological analysis was 400 401 performed by identifying the intervillous space (IVS), stem villi (SV), intermediate villi 402 (INTV), terminal villi (TV), fibrosis (FIB), syncytial knots (*); and under higher magnification 403 of terminal villi, the trophoblast cell layer (#), fetal capillaries (+) and stromal cells (^). The 404 scale bar denotes 50µm.

406 RNA extraction, cDNA synthesis and qPCR

Total RNA was extracted from n=9 control and n=6 FGR frozen placental tissues (n=1 FGR 407 408 sample was not taken due to >30 minute delay in freezing this sample) using the RNeasy 409 Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's protocol. 410 Briefly, approximately 2mg of tissue was added to 300µl of lysis buffer and homogenized using a bead-based technique. Following treatment with proteinase K and addition of 100% 411 412 ethanol, the homogenate was transferred to the spin columns, washed with supplied buffers and centrifuged to remove contaminants. Purified RNA was then eluted into RNase-free water. 413 414 Quality and concentration of extracted RNA were determined by Nanodop (Thermo Fisher 415 Scientific, Waltham, CA, USA).

416

417 Complementary DNA (cDNA) was synthesized using the Applied Biosystems High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) according to manufacturer's 418 instructions on a thermal cycler. Real-time PCR was performed in duplicate using TaqManTM 419 420 Universal Master Mix II, with UNG (Thermo Fisher Scientific) and inventoried TaqMan® gene expression assay probes with either VIC and FAM fluorophores for 5 housekeeping genes 421 422 (18SrRNA, B2M, GAPDH, GUSB and YWHAZ) and 8 genes of interest (HNF1A, IGF2, 423 SLC2A1, SLC2A3, SLC38A1, SLC38A2, SLC38A4 and VEGFA) (Table 4). Only stable housekeeping genes (18S rRNA, B2M, GADPH and YWHAZ) that showed no statistically 424 425 significant differences between cases and controls were included in the housekeeper geomean calculation for normalising gene expression across samples. The relative expression of genes 426 of interest was then calculated using the $2^{-\Delta\Delta Ct}$ method. 427

- 428
- 429 **Table 4 Probes used for real-time PCR**

Analysed genes	Gene symbol	Probe ID	Fluorophore
Housekeeping	18S rRNA	Hs99999901_s1	VIC
genes	B2M	Hs00187842_m1	VIC
	GAPDH	Hs02786624_g1	VIC
	GUSB	Hs00939627_m1	VIC
	YWHAZ	Hs01122445_g1	VIC
Genes of interest	HNF1A	Hs00167041_m1	VIC
	IGF2	Hs04188276_m1	FAM
	SLC2A1	Hs00892681_m1	FAM

medRxiv preprint doi: https://doi.org/10.1101/2022.05.31.22275522; this version posted February 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a	CC-BY 4.0	International	license.
------------------------------	-----------	---------------	----------

SLC2A3	Hs00359840_m1	FAM
SLC38A1	Hs01562175_m1	FAM
SLC38A2	Hs01089954_m1	VIC
SLC38A4	Hs00394339_m1	FAM
VEGFA	Hs00900055_m1	FAM

430

431 Histological preparation

Following paraformaldehyde fixation, biopsies of 8 sites from each control (n=9) and FGR
(n=7) placenta were embedded in paraffin using routine histological techniques and sectioned
at 7µm thickness. Sections were rehydrated using xylene and ethanol gradients, stained with
haematoxylin and eosin, dehydrated with ethanol gradients and xylene, then mounted with
DPX. Slides were then scanned using a Nanozoomer digital slide scanner (Hamamatsu
Photonics, Shizuoka Prefecture, Japan).

438

439 Placental stereology

Placentas were analysed blinded to the diagnosis of FGR. To perform stereological analysis in 440 a manner similar to that performed previously⁶³; transparent lattices with test points, test lines 441 442 or test arcs were superimposed onto scanned images viewed under different magnification on the NDP.view2 software (Hamamatsu Photonics). Volume densities of the intervillous space, 443 444 stem villi, intermediate villi, terminal villi, syncytial knots, and fibrosis (Figure 4B-C) were estimated by point counting and a lattice of equally spaced test points arranged 4 by 4 under 445 446 10X magnification in at least 13 fields of view for a minimum of 200 measurements per section. 447 Volume densities of the trophoblast, stroma, and fetal capillaries (Figure 4D) within villi were 448 estimated under a similar lattice under 40X magnification in 20 fields of view per sample. 449 Absolute placental volumes were estimated by multiplying volume densities with placental weight (g). Arithmetic barrier thickness was assessed under 100X magnification in 20 fields of 450 451 view per sample and a superimposed lattice with equally spaced straight test lines, which at 452 times, intersected fetal capillary and villous trophoblast involved in exchange. The 'measure' 453 tool within the software was then used to determine the shortest distance between a fetal 454 capillary and the maternal blood space, where there was an intersection. Mean harmonic barrier thickness was calculated using the inverse of mean reciprocal of each raw arithmetic barrier 455 thickness measurement. Thickness uniformity index, as a measure of the variability in 456 thickness across the villous membrane, was obtained from the ratio of the mean arithmetic 457

458 barrier thickness to the mean harmonic barrier thickness. Surface densities were approximated by counting chance intersections of fetal capillaries and villous trophoblast involved in 459 460 exchange with superimposed test arc lines under 40X magnification. To derive surface areas, 461 surface densities were multiplied by placental villous volume. The theoretical diffusion 462 capacity was calculated using the total surface area for exchange (averaged surface area of fetal capillaries and villi) divided by the mean harmonic barrier thickness and multiplied by Krogh's 463 464 constant for oxygen diffusion. Specific diffusion capacity was then calculated by dividing the 465 theoretical diffusion capacity by the infant birthweight.

466

467 *Predictive modelling*

468 To evaluate the informativity of different placental sampling locations (only peripheral, only central or both regions together) and different data types (only stereological data, only PCR 469 470 data or both types together), we studied all their possible combinations with analysis performed 471 in R (version 4.0.2). To analyse several well-established multi-dimensional methods of data 472 analysis, the machine learning models (*xgbTree*, *glmnet* and *nnet*) were implemented using 473 *caret* package (version 6.0.90). All 27 models were trained with default set of hyperparameters, 474 cross-validated on 5 folds (for a better selection of internal algorithm parameters), with seed 475 parameter set to 123. The performance of models was assessed with receiver operating characteristic (ROC) curves using area under the curve (AUC) with 95% confidence intervals 476 477 (*pROC* package, version 1.18.0). Results of AUCs were presented in two ways:

478 - *All sample's AUC* - Calculating AUC considering all samples as independent;

All patient's AUC - Calculating AUC on patient's result's only (if all samples belonging
to one patient were correctly predicted, then we assumed that a prediction for this
patient was correct, if the prediction was wrong in at least one sample of the sample's
patient, then it was set as wrong for this patient).

For illustration of interdependencies of features, which are presented in Supplementary Figure
1, we selected the best pairs that showed significant differences between FGR and control
groups using ANOVA test after applying FDR (false discovery rate) adjustment to test's pvalues (*stats* package, Version 4.0.2).

487

488 *Statistical analyses*

489 Normality of data was assessed by D'Agostino-Pearson normality test. ROUT testing for 490 outliers was used to identify any outliers, which were then excluded from the analysis. For 491 comparisons between 2 groups, Student's t tests and Mann-Whitney U tests were performed

492 for parametric and non-parametric continuous data, respectively. Categorical data between FGR and controls were analysed by a 2 X 2 contingency table with Fisher's Exact Test. Two-493 494 way ANOVAs followed by Sidak post hoc test for multiple comparisons were used to analyse 495 mRNA expression data by pathology and sampling location. Graphpad Prism 6.01 (Graphpad 496 Software Inc., La Jolla, CA, USA) was used for statistical analyses. A p-value of <0.05 was considered statistically significant for clinical characteristics and mRNA expression analysis. 497 498 To account for multiple testing in histological analyses, a false discovery rate correction at 5% 499 was applied to determine statistical significance.

500

501 Acknowledgements

502 ANSP received funding for this work via an Academy of Medical Sciences Springboard Grant, 503 Dorothy Hodgkin Research Fellowship (DH130036/RG74249), MRC New Investigator Grant 504 (MR/R022690/1/RG93186) and Lister Institute of Preventative Medicine Research Prize (RG93692). TN and AZ are supported by a Medical Research Council grant (MR/R02524X/1). 505 506 HEJY was supported by an A*STAR International Fellowship from the Agency for Science, 507 Technology and Research. KM was supported by UCLH Charity and the Mitchell Charitable 508 Trust. SLH received funding for this work via an Academy of Medical Sciences Clinical 509 Lecturer Starter Grant and the UCLH EGA Obstetric Charity.

510

511 **Author contributions**

HEJY, KM, SLH and ANSP designed the study. HEJY, KM, MABY, ESP collected and/or 512 513 performed experiments. HEJY, KM, ESP and TN analysed and graphed the data. TN and AZ 514 provided predictive modelling analysis. HEJY, KM, TN, AZ, ALD, SLH and ANSP interpreted 515 the data. HEJY, KM, SLH and ANSP wrote the paper. All authors performed final editing 516 checks and approved the final manuscript. 517

- 518

519 References

521 522	1	Napso, T., Yong, H. E., Lopez-Tello, J. & Sferruzzi-Perri, A. N. The role of placental hormones in mediating maternal adaptations to support pregnancy and lactation.
523		<i>Front Physiology</i> 9:1091 , doi:10.3389/fphys.2018.01091 (2018).
524	2	Burton, G. J., Fowden, A. L. & Thornburg, K. L. Placental Origins of Chronic Disease.
525		<i>Physiological reviews</i> 96 , 1509-1565, doi:10.1152/physrev.00029.2015 (2016).
526	3	Byrne, M. et al. Structure-function relationships in the feto-placental circulation
527		from in silico interpretation of micro-CT vascular structures. J Theor Biol 517,
528		110630, doi:10.1016/j.jtbi.2021.110630 (2021).
529	4	Aughwane, R. et al. Micro-CT and histological investigation of the spatial pattern of
530		feto-placental vascular density. <i>Placenta</i> 88, 36-43,
531		doi:10.1016/j.placenta.2019.09.014 (2019).
532	5	World Health, O. Every newborn: an action plan to end preventable deaths. 55 p.
533		(World Health Organization, 2014).
534	6	Lawn, J. E. <i>et al.</i> Every Newborn: progress, priorities, and potential beyond survival.
535		Lancet 384 , 189-205, doi:10.1016/S0140-6736(14)60496-7 (2014).
536	7	Sharma, D., Shastri, S. & Sharma, P. Intrauterine Growth Restriction: Antenatal and
537		Postnatal Aspects. Clin Med Insights Pediatr 10, 67-83, doi:10.4137/CMPed.S40070
538		(2016).
539	8	Gordijn, S. J. et al. Consensus definition of fetal growth restriction: a Delphi
540		procedure. Ultrasound Obstet Gynecol 48, 333-339, doi:10.1002/uog.15884 (2016).
541	9	Van den Berg, B. J. & Yerushalmy, J. The relationship of the rate of intrauterine
542		growth of infants of low birth weight to mortality, morbidity, and congenital
543		anomalies. <i>J Pediatr</i> 69 , 531-545, doi:10.1016/s0022-3476(66)80038-0 (1966).
544	10	Bianchi, M. E. & Restrepo, J. M. Low Birthweight as a Risk Factor for Non-
545		communicable Diseases in Adults. Front Med (Lausanne) 8, 793990,
546		doi:10.3389/fmed.2021.793990 (2021).
547	11	Caradeux, J., Martinez-Portilla, R. J., Basuki, T. R., Kiserud, T. & Figueras, F. Risk of
548		fetal death in growth-restricted fetuses with umbilical and/or ductus venosus absent
549		or reversed end-diastolic velocities before 34 weeks of gestation: a systematic
550		review and meta-analysis. Am J Obstet Gynecol 218 , S774-S782 e721,
551		doi:10.1016/j.ajog.2017.11.566 (2018).
552	12	Ishihara, N. et al. Increased apoptosis in the syncytiotrophoblast in human term
553		placentas complicated by either preeclampsia or intrauterine growth retardation.
554		Am J Obstet Gynecol 186, 158-166, doi:10.1067/mob.2002.119176 (2002).
555	13	Mayhew, T. M., Wijesekara, J., Baker, P. N. & Ong, S. S. Morphometric evidence that
556		villous development and fetoplacental angiogenesis are compromised by
557		intrauterine growth restriction but not by pre-eclampsia. <i>Placenta</i> 25 , 829-833,
558		doi:10.1016/j.placenta.2004.04.011 (2004).
559	14	Macara, L. et al. Structural analysis of placental terminal villi from growth-restricted
560		pregnancies with abnormal umbilical artery Doppler waveforms. Placenta 17, 37-48,
561		doi:10.1016/s0143-4004(05)80642-3 (1996).
562	15	Teasdale, F. & Jean-Jacques, G. Intrauterine growth retardation: morphometry of the
563		microvillous membrane of the human placenta. <i>Placenta</i> 9 , 47-55 (1988).

medRxiv preprint doi: https://doi.org/10.1101/2022.05.31.22275522; this version posted February 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

porporation	•
It is made available under a CC-BY	4.0 International license .

564	16	Burton G I & Fowden A I. The placenta: a multifaceted transient organ Philos
565	10	Trans R Soc Lond B Biol Sci 370 20140066 doi:10.1098/rstb.2014.0066 (2015)
566	17	Chavatte-Palmer P & Tarrade A Placentation in different mammalian species Ann
567	17	Endocrinol (Paris) 77, 67-74, doi:10.1016/i.ando.2016.04.006 (2016)
568	18	Pere M C Materno-foetal exchanges and utilisation of nutrients by the foetus:
560	10	comparison between species. <i>Reprod Nutr Dev</i> 13 , 1-15, doi:10.1051/rpd:2003002
570		(2003)
570	10	(2003). Crawford M. A. Hassam A. G. & Williams G. Essential fatty acids and fotal brain
572	19	growth $Lancet 1$ 452-453 doi:10.1016/s0140-6736/76)91476-8 (1976)
572	20	Gresham E. L. Simons, D. S. & Battaglia, E. C. Maternal-fetal urea concentration
574	20	difference in man: metabolic significance. <i>L Padiatr</i> 79 , 809-811, doi:10.1016/s0022-
575		2476(71)80206-7 (1071)
575	21	Storyuzzi Derri A. N. et al. Discental specific laf2 deficiency alters developmental
570	21	sterruzzi-rent, A. N. <i>et ul.</i> Placental-specific Igiz denciency alters developmental
5//		dei:10.1210/on.2011.0240.(2011)
5/8	22	dol:10.1210/efi.2011-0240 (2011).
579	22	Sterruzzi-Pern, A. N. <i>et al.</i> An obesogenic diet during mouse pregnancy modifies
580		maternal nutrient partitioning and the retai growth trajectory. Faseb J 21 , 3928-
581	22	3937, 001:10.1096/fJ.13-234823 (2013).
582	23	vaugnan, U. R., Sterruzzi-Perri, A. N. & Fowden, A. L. Maternal corticosterone
583		regulates nutrient allocation to fetal growth in mice. The Journal of physiology 590,
584	24	5529-5540 (2012).
585	24	Higgins, J. S., Vaugnan, O. R., de Liger, E. F., Fowden, A. L. & Sterruzzi-Perri, A. N.
586		Placental phenotype and resource allocation to fetal growth are modified by the
587		timing and degree of hypoxia during mouse pregnancy. J Physiol 594 , 1341-1356,
588	a -	
589	25	Napso, I., Hung, Y. P., Davidge, S. I., Care, A. S. & Sferruzzi-Perri, A. N. Advanced
590		maternal age compromises fetal growth and induces sex-specific changes in
591		placental phenotype in rats. <i>Sci Rep</i> 9 , 16916, doi:10.1038/s41598-019-53199-x
592		
593	26	Lewis, R. M. & Sterruzzi-Perri, A. N. in <i>Developmental Origins of Health and Disease</i>
594		(eds L. Poston, K. M. Godfrey, M. A. Hanson, & P. Gluckman) (Cambridge University
595	<u>-</u>	Press).
596	27	Audette, M. C., McLaughlin, K. & Kingdom, J. C. Second Trimester Placental Growth
597		Factor Levels and Placental Histopathology in Low-Risk Nulliparous Pregnancies. J
598		<i>Obstet Gynaecol Can</i> 43 , 1145-1152 e1141, doi:10.1016/j.jogc.2021.01.018 (2021).
599	28	Burton, G. J. <i>et al.</i> Optimising sample collection for placental research. <i>Placenta</i> 35 ,
600		9-22, doi:10.1016/j.placenta.2013.11.005 (2014).
601	29	Mayhew, T. M. Taking tissue samples from the placenta: an illustration of principles
602		and strategies. <i>Placenta</i> 29 , 1-14, doi:10.1016/j.placenta.2007.05.010 (2008).
603	30	Mayhew, T. M. Morphomics: An integral part of systems biology of the human
604		placenta. <i>Placenta</i> 36 , 329-340, doi:10.1016/j.placenta.2015.01.001 (2015).
605	31	Salafia, C. M. et al. Placental surface shape, function, and effects of maternal and
606		fetal vascular pathology. <i>Placenta</i> 31 , 958-962, doi:10.1016/j.placenta.2010.09.005
607		(2010).
608	32	Gordon, Z. et al. Anthropometry of fetal vasculature in the chorionic plate. J Anat
609		211 , 698-706, doi:10.1111/j.1469-7580.2007.00819.x (2007).

p0.p0	toney.
is made available under a CO	C-BY 4.0 International license.

610	33	Heifetz, S. A. The umbilical cord: obstetrically important lesions. <i>Clin Obstet Gynecol</i>
611		39 , 571-587, doi:10.1097/00003081-199609000-00007 (1996).
612	34	Sferruzzi-Perri, A. N. & Camm, E. J. The programming power of the placenta.
613		Frontiers in Physiology 7:33 , doi:10.3389/fphys.2016.00033 (2016).
614	35	Vaughan, O. R. <i>et al.</i> Placenta-specific Slc38a2/SNAT2 knockdown causes fetal
615		growth restriction in mice. Clin Sci (Lond) 135, 2049-2066, doi:10.1042/CS20210575
616		(2021).
617	36	Luscher, B. P. <i>et al.</i> Placental glucose transporter (GLUT)-1 is down-regulated in
618		preeclampsia. <i>Placenta</i> 55 , 94-99, doi:10.1016/j.placenta.2017.04.023 (2017).
619	37	Ganguly, A. <i>et al.</i> Glucose transporter isoform-3 mutations cause early pregnancy
620		loss and fetal growth restriction. American journal of physiology 292 , E1241-1255
621		(2007).
622	38	Sferruzzi-Perri, A. N., Owens, J. A., Pringle, K. G. & Roberts, C. T. The neglected role
623		of insulin-like growth factors in the maternal circulation regulating fetal growth. The
624		Journal of physiology 589 , 7-20 (2010).
625	39	Sferruzzi-Perri, A. N., Sandovici, I., Constancia, M. & Fowden, A. L. Placental
626		phenotype and the insulin-like growth factors: resource allocation to fetal growth.
627		The Journal of physiology 595 , 5057-5093 (2017).
628	40	Mifsud, W. & Sebire, N. J. Placental pathology in early-onset and late-onset fetal
629		growth restriction. <i>Fetal Diagn Ther</i> 36 , 117-128, doi:10.1159/000359969 (2014).
630	41	Brosens, I., Piinenborg, R., Vercruvsse, L. & Romero, R. The "Great Obstetrical
631		Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol
632		204 , 193-201, doi:10.1016/j.ajog.2010.08.009 (2011).
633	42	Burton, G. J. & Jauniaux, E. Pathophysiology of placental-derived fetal growth
634		restriction. Am J Obstet Gynecol 218 , S745-S761, doi:10.1016/j.ajog.2017.11.577
635		(2018).
636	43	Kovo, M. <i>et al.</i> Placental vascular lesion differences in pregnancy-induced
637		hypertension and normotensive fetal growth restriction. Am J Obstet Gynecol 202 ,
638		561 e561-565, doi:10.1016/j.ajog.2010.01.012 (2010).
639	44	Colson, A., Sonveaux, P., Debieve, F. & Sferruzzi-Perri, A. N. Adaptations of the
640		human placenta to hypoxia: opportunities for interventions in fetal growth
641		restriction. Hum Reprod Update, doi:10.1093/humupd/dmaa053 (2020).
642	45	Cindrova-Davies, T. & Sferruzzi-Perri, A. N. Human placental development and
643		function. Seminars in Cell and Developmental Biology In press (2022).
644	46	David, A. L. et al. Local delivery of VEGF adenovirus to the uterine artery increases
645		vasorelaxation and uterine blood flow in the pregnant sheep. Gene Ther 15, 1344-
646		1350, doi:10.1038/gt.2008.102 (2008).
647	47	Sferruzzi-Perri, A. N. Regulating needs: Exploring the role of insulin-like growth
648		factor-2 signalling in materno-fetal resource allocation. <i>Placenta</i> Suppl 1 , S16-S22,
649		doi:10.1016/j.placenta.2018.01.005 (2018).
650	48	Guo, L. <i>et al.</i> Altered gene expression and methylation of the human chromosome
651		11 imprinted region in small for gestational age (SGA) placentae. Dev Biol 320 , 79-91,
652		doi:10.1016/j.ydbio.2008.04.025 (2008).
653	49	Yamaguchi, Y. et al. Placenta-specific epimutation at H19-DMR among common
654		pregnancy complications: its frequency and effect on the expression patterns of H19
655		and IGF2. <i>Clin Epigenetics</i> 11 , 113, doi:10.1186/s13148-019-0712-3 (2019).

medRxiv preprint doi: https://doi.org/10.1101/2022.05.31.22275522; this version posted February 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

		It is made available under a CC-BY 4.0 International license .
656 657	50	Antonazzo, P. <i>et al.</i> Placental IGF2 Expression in Normal and Intrauterine Growth Restricted (IUGR) Pregnancies. <i>Placenta</i> 29 , 99-101 (2008).
658	51	Janzen, C. <i>et al.</i> Placental glucose transporter 3 (GLUT3) is up-regulated in human
659 660		pregnancies complicated by late-onset intrauterine growth restriction. <i>Placenta</i> 34 , 1072-1078, doi:10.1016/j.placenta.2013.08.010 (2013).
661	52	Desforges, M., Greenwood, S. L., Glazier, J. D., Westwood, M. & Sibley, C. P. The
662		contribution of SNAT1 to system A amino acid transporter activity in human
663		placental trophoblast. Biochem Biophys Res Commun 398 , 130-134,
664		doi:10.1016/j.bbrc.2010.06.051 (2010).
665	53	Shibata, E. et al. Placental System A Amino Acid Transport is Reduced in Pregnancies
666		With Small For Gestational Age (SGA) Infants but Not in Preeclampsia with SGA
667		Infants. <i>Placenta</i> 29 , 879-882 (2008).
668	54	Lash, G. et al. Abnormal fetal growth is not associated with altered chorionic villous
669		expression of vascular endothelial growth factor mRNA. <i>Mol Hum Reprod</i> 7, 1093-
670		1098, doi:10.1093/molehr/7.11.1093 (2001).
671	55	Lyall, F., Young, A., Boswell, F., Kingdom, J. C. & Greer, I. A. Placental expression of
672		vascular endothelial growth factor in placentae from pregnancies complicated by
673		pre-eclampsia and intrauterine growth restriction does not support placental
674		hypoxia at delivery. <i>Placenta</i> 18 , 269-276, doi:10.1016/s0143-4004(97)80061-6
675		(1997).
676	56	Andraweera, P. H., Dekker, G. A. & Roberts, C. T. The vascular endothelial growth
677		factor family in adverse pregnancy outcomes. Hum Reprod Update 18, 436-457,
678		doi:10.1093/humupd/dms011 (2012).
679	57	Krishnan, T. & David, A. L. Placenta-directed gene therapy for fetal growth
680		restriction. Semin Fetal Neonatal Med 22, 415-422, doi:10.1016/j.siny.2017.04.005
681		(2017).
682	58	Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347,
683		1260419, doi:10.1126/science.1260419 (2015).
684	59	Human Protein Atlas Team. Human Protein Atlas - HNF1A in the placenta,
685		< <u>https://www.proteinatlas.org/ENSG00000135100-HNF1A/tissue/placenta</u> >(
686	60	Ducat, A. et al. Low-dose aspirin protective effects are correlated with deregulation
687		of HNF factor expression in the preeclamptic placentas from mice and humans. <i>Cell</i>
688		Death Discov 5, 94, doi:10.1038/s41420-019-0170-x (2019).
689	61	Rout, M. & Lulu, S. S. Molecular and disease association of gestational diabetes

- 689 betes 690 mellitus affected mother and placental datasets reveal a strong link between insulin 691 growth factor (IGF) genes in amino acid transport pathway: A network biology 692 approach. J Cell Biochem, doi:10.1002/jcb.27418 (2018).
- 693 Brenner, W. E., Edelman, D. A. & Hendricks, C. H. A standard of fetal growth for the 62 694 United States of America. Am J Obstet Gynecol 126, 555-564, doi:10.1016/0002-695 9378(76)90748-1 (1976).
- 696 Mayhew, T. M. Stereology and the placenta: where's the point? -- a review. Placenta 63 697 **27 Suppl A**, S17-25, doi:10.1016/j.placenta.2005.11.006 (2006).
- 698
- 699
- 700

701 SUPPLEMENTARY INFORMATION

702 Supplementary Table 1: Full phenotype clinical data.

ID	Status	Medical history	Pregnancy complications	Maternal age quartile (years)	Ethnicity	Maternal booking BMI	Delivery mode	Gestat ion	Birthweight (g)	Infant sex	Placenta weight (g)	Placenta/ BW ratio (%)	Analysis comments
Control 1	Control			31-35	Asian	34	Vaginal delivery	39+6	3200	Male	442	13.8	
Control 2	Control			36-40	White	21	cat4 CS	39+1	3690	Female	516	14.0	
Control 3	Control			21-25	White	20	Vaginal delivery	39+0	3800	Female	534	14.1	
Control 4	Control			31-35	White	23	cat3 CS	41+1	3970	Male	509	12.8	
Control 5	Control			41-45	White	27	cat4 CS	39+1	3960	Female	481	12.1	
Control 6	Control			36-40	White	24	cat4 CS	39+1	2893	Female	413	14.3	
Control 7	Control			36-40	White	23	Vaginal delivery	39+0	3618	Male	491	13.6	
Control 8	Control			36-40	White	23	cat4 CS	39+1	3140	Male	398	12.7	
Control 9	Control			31-35	White	28	Vaginal delivery	39+5	3510	Male	526	15.0	
FGR 1	Late FGR			31-35	White	23	cat3 CS	37+0	1410	Male	160	11.3	

FGR 2	Late FGR	Hypothyroid		31-35	White	22	Vaginal delivery	37+5	2510	Female	346	13.8	
FGR 3	Late FGR	Migraines		31-35	Chinese	22	cat2 CS	37+2	2560	Male	380	14.8	
FGR 4	Late FGR		Low platelets	26-30	Afro Caribbean	22	cat2 CS	38+2	1985	Male	380	19.1	
FGR 5	Late FGR			31-35	Chinese	20	Vaginal delivery	39+4	2720	Female	360	13.2	
FGR 6	Late FGR		Gestational diabetes	31-35	Asian	38	cat1 CS	38+4	2396	Male	355	14.8	
FGR 7	Late FGR			36-40	Afro Caribbean	28	cat3 CS	39+0	2750	Male	404	14.7	Not run for qPCR

703

704 CS = caesarean section. Cat1 = Immediate threat to the life of the woman or fetus, Cat2 = Maternal or fetal compromise which is not immediately

⁷⁰⁵ life-threatening, Cat³ = No maternal or fetal compromise but needs early birth, Cat⁴ = Birth timed to suit woman or healthcare provider. (NICE

706 guideline 192: Caesarean birth, published 31 March 2021).

	Control (N=9)			FGR (N=7)		
	Central	Peripheral	P-value	Central	Peripheral	P-value
Volume density (cm ³ /g)						
Intervillous space	0.39±0.02	0.36±0.01	0.130	0.36±0.02	0.35±0.02	0.577
Stem villi	0.06±0.01	0.06±0.01	0.902	0.06±0.02	0.05±0.01	0.364
Intermediate villi	0.1±0.01	0.13±0.01	0.105	0.08±0.01	0.08±0.01	0.720
Terminal villi	0.42±0.02	0.42±0.02	0.941	0.41±0.03	0.38±0.03	0.526
Syncytial knots	0.02±0.00	0.02±0.00	0.633	0.01±0.00	0.01±0.00	0.591
Fibrosis	0.01±0.00	0.02±0.01	0.443	0.07±0.02	0.13±0.03	0.091
Trophoblast	0.33±0.02	0.31±0.01	0.492	0.34±0.02	0.33±0.04	0.818
Stromal	0.53±0.03	0.57±0.02	0.239	0.45±0.04	0.46±0.06	0.865
Capillary	0.14±0.01	0.12±0.01	0.139	0.21±0.03	0.21±0.03	0.963
Volume (cm ³)						
Intervillous space	187.75±10.19	171.7±9.96	0.277	121.96±11.52	116.92±10.14	0.748
Stem villi	27.82±5.18	27.85±2.89	0.100	23.24±6.3	17.1±2.58	0.385
Intermediate villi	49.91±4.81	60.89±5.94	0.170	24.77±2.83	26.19±2.23	0.700
Terminal villi	199.23±8.7	202.24±13.7	0.855	141.08±17.48	129.51±15.51	0.630
Syncytial knots	8.89±0.9	7.89±1.12	0.495	2.24±0.66	2.63±0.82	0.720
Fibrosis	3.9±1.93	7.87±4.69	0.446	26.28±6.89	47.77±9.57	0.094
Trophoblast	156.49±6.76	150.51±8.25	0.583	117.28±13.22	112.13±15.07	0.802

Supplementary Table 2: Morphological differences in the placenta by sampling location.

Stromal	254.68±18.75	271.49±12.97	0.472	150.39±19.02	156.07±25.00	0.860
Capillary	67.72±5.88	56.89±5.04	0.181	73.05±14.18	72.51±13.58	0.979
Barrier thickness (µm)						
Arithmetic mean	2.84±0.08	2.82±0.10	0.885	2.84±0.19	2.86±0.18	0.940
Harmonic mean	2.14±0.07	2.15±0.07	0.918	2.24±0.15	2.24±0.14	0.987
Thickness uniformity index	1.33±0.02	1.31±0.02	0.508	1.47±0.08	1.48±0.08	0.936
Surface density (cm ² /cm ³)						
Villi	613.67±27.94	607.22±24.07	0.863	634.49±43.19	626.07±47.42	0.898
Fetal capillary	318.63±27.71	277.88±13.62	0.206	406.06±47.11	397.78±51.52	0.906
Surface area (m ²)						
Villi	15.32±0.97	15.99±0.92	0.622	10.87±1.63	10.3±1.51	0.801
Fetal capillary	7.89±0.75	7.32±0.44	0.519	7.11±1.31	6.67±1.2	0.807
Theoretical diffusion capacity	94.95±5.96	95.64±4.31	0.926	71.63±11.95	68.89±11.61	0.872
(cm²/min/kPa)						
Specific diffusion capacity	27.15±1.86	27.24±1.23	0.968	30.24±4.58	28.7±3.71	0.798
(cm²/min/kPa/g)						

Supplementary Table 3: Summary tables of errors in all 27 models for each patient.

	ONLY PERIPHERAL												
id	score	STEREOLOGY & PCR				PCR		STEREOLOGY					
	score	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet			
Control 1	0	0of4	0of4	0of4	1of4	1of4	1of4	0of4	0of4	0of4			
Control 2	0	1of4	0of4	0of4	0of4	0of4	0of4	1of4	0of4	0of4			
Control 3	0	0of4	0of4	0of4	0of4	1of4	1of4	0of4	0of4	0of4			
Control 4	0	0of4	0of4	0of4	4of4	3of4	3of4	0of4	0of4	0of4			
Control 5	0	0of4	0of4	0of4	2of4	0of4	0of4	0of4	0of4	0of4			
Control 6	0	0of4	0of4	0of4	3of4	3of4	4of4	0of4	0of4	0of4			
Control 7	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4			
Control 8	0	0of4	0of4	0of4	1of4	2of4	2of4	0of4	0of4	1of4			
Control 9	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4			
FGR 1	1	4of4	0of4	0of4	4of4	4of4	4of4	0of4	0of4	0of4			
FGR 2	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4			
FGR 3	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4			
FGR 4	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4			
FGR 5	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4			
FGR 6	1	4of4	3of4	1of4	4of4	4of4	4of4	4of4	3of4	3of4			

	ONLY CENTRAL											
id	score	STEREOLOGY & PCR				PCR		STEREOLOGY				
iu iu	score	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet		
Control 1	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4		
Control 2	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4		
Control 3	0	0of4	0of4	0of4	2of4	2of4	0of4	0of4	0of4	0of4		
Control 4	0	0of4	0of4	0of4	2of4	3of4	3of4	0of4	0of4	0of4		
Control 5	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4		
Control 6	0	3of4	2of4	1of4	3of4	3of4	3of4	0of4	0of4	0of4		
Control 7	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4		
Control 8	0	2of4	0of4	1of4	0of4	0of4	1of4	2of4	1of4	1of4		
Control 9	0	0of4	0of4	0of4	1of4	2of4	1of4	0of4	0of4	0of4		
FGR 1	1	1of4	0of4	0of4	4of4	4of4	4of4	0of4	0of4	0of4		
FGR 2	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4		
FGR 3	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4		
FGR 4	1	0of4	0of4	0of4	0of4	0of4	0of4	1of4	0of4	0of4		
FGR 5	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4		
FGR 6	1	4of4	4of4	4of4	4of4	4of4	4of4	3of4	4of4	4of4		

	CENTRAL & PERIPHERAL												
id	ccoro	STEREOLOGY & PCR				PCR		STEREOLOGY					
iù	score	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet			
Control 1	0	1of8	0of8	0of8	1of8	1of8	1of8	1of8	0of8	0of8			
Control 2	0	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8			
Control 3	0	0of8	0of8	0of8	1of8	2of8	2of8	0of8	0of8	0of8			
Control 4	0	0of8	0of8	0of8	5of8	2of8	5of8	0of8	0of8	0of8			
Control 5	0	0of8	0of8	0of8	2of8	0of8	0of8	0of8	0of8	0of8			
Control 6	0	3of8	1of8	0of8	6of8	7of8	6of8	0of8	0of8	0of8			
Control 7	0	0of8	0of8	0of8	0of8	0of8	0of8	1of8	0of8	0of8			
Control 8	0	1of8	0of8	0of8	1of8	1of8	1of8	1of8	2of8	0of8			
Control 9	0	1of8	0of8	0of8	1of8	0of8	0of8	1of8	0of8	0of8			
FGR 1	1	0of8	0of8	0of8	8of8	8of8	8of8	0of8	0of8	0of8			
FGR 2	1	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8			
FGR 3	1	0of8	0of8	0of8	1of8	0of8	0of8	1of8	0of8	0of8			
FGR 4	1	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8			
FGR 5	1	0of8	0of8	0of8	0of8	1of8	1of8	0of8	0of8	0of8			
FGR 6	1	8of8	7of8	5of8	8of8	8of8	8of8	6of8	7of8	7of8			

Each cell for each patient and 27 models considered (different columns) indicates how many wrong predictions were made for this patient among all 4 or 8 available samples (for example, the entry 0of4 means that 0 errors were made among 4 predictions). The cell is highlighted in

red if at least one mistake was made for the patient. Third column in the first panel corresponds to the best model, using nnet ML algorithm, and both stereology and PCR data for peripheral samples. This model returns only one wrong prediction out of 60 samples considered.



Supplementary Figure 1: Different interdependencies of features for stereological data.

Different interdependencies of features for Control (blue colour) and FGR (red colour) on stereological data. Each point is a separate patient measurement, each line connects all measurements for each patient. For many pairs of features, a separation between FGR cases and controls was easily seen, hence, enabling a construction of a successful predictive model.